Nanjing Leads Biolabs Co., Ltd. (HKG:9887)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
52.05
+1.65 (3.27%)
Sep 30, 2026, 4:08 PM HKT

Nanjing Leads Biolabs Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Nanjing Leads Biolabs stock has a consensus rating of "Strong Buy" and an average price target of $105.54. The average 1-year stock price forecast is 102.77% higher than the current stock price, while the lowest is $93.07 (+78.81%) and the highest is $117.15 (+125.07%).

Price Target: $105.54 (+102.77%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$93.07$105.54$107.85$117.15
Change+78.81%+102.77%+107.20%+125.07%

Analyst Ratings

The average analyst rating for Nanjing Leads Biolabs stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jul '26Aug '26Sep '26
Strong Buy222223
Buy111112
Hold111110
Sell000000
Strong Sell000000
Total444445

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
Morgan Stanley
No rating
Morgan Stanley
Buy
Upgrades
$79.00 → $93.00
BuyUpgrades$79.00 → $93.00+78.67%Sep 16, 2026
Unknown Analyst
Shenwan Hongyuan
No rating
Shenwan Hongyuan
Buy
Maintains
$108.89
BuyMaintains$108.89+109.20%Sep 11, 2026
Unknown Analyst
SDIC Securities
No rating
SDIC Securities
Buy
Maintains
$83.34
BuyMaintains$83.34+60.12%Sep 4, 2026
CMB International Securities
CMB International Securities
Buy
Reiterates
$100.50
BuyReiterates$100.50+93.08%Sep 3, 2026
Unknown Analyst
CLSA
No rating
CLSA
Buy
Maintains
$108.00
BuyMaintains$108.00+107.49%Jul 13, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
269.47M
from 177.26M
Increased by 52.02%
Revenue Next Year
444.58M
from 269.47M
Increased by 64.98%
EPS This Year
-0.95
from -1.03
EPS Next Year
-1.31
from -0.95
Fiscal YearFY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
8.87M-177.26M269.47M
Revenue Growth
---52.02%
Gross Profit
5.68M-177.26M267.99M
Gross Margin
64.07%-100.00%99.45%
Operating Income
-263.23M-273.38M-194.53M11.00M
Net Income
-362.25M-301.22M-211.42M-209.02M
EPS
---1.03-0.95
Free Cash Flow
---162.65M-260.18M
No. Analysts
---5
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High322.0M
Avg269.5M
Low236.0M

Revenue Growth

Revenue Growth202620272028
High
81.7%
Avg
52.0%
Low
33.1%

EPS Forecast

EPS202620272028
High-0.76
Avg-0.95
Low-1.14

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-